Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model

Cancer Investigation

Volumn 30, Issue 3, 2012, Pages 243-250

  Goodwin, Jonathan M ^a   Schmitt, Anthony D ^a   McGinn, Christopher M ^a   Fuchs, Bryan C ^a   Kuruppu, Darshini ^a   Tanabe, Kenneth K ^a   Lanuti, Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Endostatin; Herpes simplex virus; Lung cancer; Viral oncolysis

Indexed keywords

ENDOSTATIN; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TRANSGENE; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; VIRUS MUTANT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENDOSTATINS; ENDOTHELIAL CELLS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; TRANSGENES;

EID: 84857536857     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.654870     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, Sawaki M, Kikumori T, Kodera Y, Nagasaka T, Goshima F, Nishiyama Y, Imai T. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets 2007;7:169-174. (Pubitemid 46348631)
3. Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-6747. (Pubitemid 44876843)
4. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 2008;9:533-542.
5. Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial.World J Gastroenterol 2004;10:3634-3638. (Pubitemid 39619282)
6. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-856. (Pubitemid 121000529)
7. Reinblatt M, Pin RH, Fong Y. Herpes viral oncolysis: A novel cancer therapy. J Am Coll Surg 2007;205:S69-S75. (Pubitemid 47488925)
8. Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 2005;4:524-531. (Pubitemid 41351224)
9. DeRubertis BG, Stiles BM, Bhargava A, Gusani NJ, Hezel M, D'Angelica M, Fong Y. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007;14:590-597. (Pubitemid 46788334)
10. Tyminski E, LeRoy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, Potter PM, Saeki Y, Chiocca EA. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005;65:6850-6857. (Pubitemid 41060724)
11. Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 2005;7:213-224. (Pubitemid 41079131)
12. Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK. Oncolysis by viral replication and inhibition of angiogenesis by a replicationconditional herpes simplex virus that expresses mouse endostatin. Cancer 2004;101:869-877. (Pubitemid 39030946)
13. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285. (Pubitemid 28015876)
14. Abdollahi A, Hahnfeldt P, Maercker C, Gr̈one HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-663.
15. Wickstr̈om SA, Alitalo K, Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv Cancer Res 2005;94:197-229. (Pubitemid 41202366)
16. Yoon SS, EtoH, LinCM, NakamuraH, Pawlik TM, Song SU, Tanabe KK.Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251-6256. (Pubitemid 30035650)
17. Goldstein DJ,Weller SK. Factor(s) present in herpes simplex virus type-1 infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988;166:41-51.
18. Kulu Y, Dorfman JD, Kuruppu D, Fuchs BC, Goodwin JM, Fujii T, Kuroda T, Lanuti M, Tanabe KK. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 2009;16:291-297.
19. Spear PG, Longnecker R. Herpesvirus entry: An update. J Virol 2003;77:10179-10185. (Pubitemid 37129662)
20. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. A novel role for 3- O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999;99:13-22. (Pubitemid 29468626)
21. Sandberg WJ, Halvorsen B, Yndestad A, Smith C, Otterdal K, Brosstad FR, Froland SS, Olofsson PS, Damas JK, Gullestad L, HanssonGK,Oie E,Aukrust P. Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis. Circ Res 2009;104:60-68.
22. Shukla D, Scanlan PM, Tiwari V, Sheth V, Clement C, Guzman- Hartman G, Dermody TS, Valyi-Nagy T. Expression of nectin-1 in normal and herpes simplex virus type-1-infectedmurine brain. Appl Immunohistochem Mol Morphol 2006;14:341-347. (Pubitemid 44319062)
23. Florian JA, Kosky JR,Ainslie K, Pang Z, Dull RO, Tarbell JM.Heparan sulfate proteogylcan is amechanosensor on endothelial cells. Circ Res 2003;93:136-142.
24. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999;17:343-348. (Pubitemid 29166035)
25. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-7674. (Pubitemid 32995064)
26. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibodyendostatin fusion protein. Mol CancerTher 2005;4:956-967. (Pubitemid 40909078)
27. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravada EA, Lo KM, Gillies SD, Folkman J, Javaherian K. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008;14:1487-1493. (Pubitemid 351413933)
28. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Curr Cancer Drug Targets 2007;7:149-155. (Pubitemid 46348629)
29. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Therapy 2003;10:983-990. (Pubitemid 36722433)
30. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C. Prostaterestricted replicative adenovirus expressing human endostatinangiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res 2008;14:291-299. (Pubitemid 351378005)
31. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by upregulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-1539. (Pubitemid 351413938)
32. Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y, Fuchs BC, Kawasaki H, Tanabe KK. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res 2007;67:3295-3300. (Pubitemid 46724868)